FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997559766> ?p ?o ?g. }

• W1997559766 endingPage "955" @default.
• W1997559766 startingPage "949" @default.
• W1997559766 abstract "Experimental and clinical data implicate inadequate erythropoletin production as an important reason that infants acquire this anemia and suggest that recombinant human erythropoletin (r-HuEPO) might be used to treat or prevent it. We therefore randomly assigned 20 small premature infants (birth weight ≤1250 gm) who were highly likely to require erythrocyte transfusions for anemia of prematurity to receive 6 weeks of treatment with either intravenously administered r-HuEPO (at a dose of 100 units/kg twice each week) or a placebo. Hematologic measurements, transfusion requirements, and growth were followed during therapy and for 6 months thereafter. Treated (EPO) and control babies did not differ with respect to weight, hematocrit, overall mean absolute reticulocyte count, calculated erythrocyte mass, or rate of growth. However, reticulocyte counts increased earlier in patients given r-HuEPO. Six of ten babies in the EPO group, and 8 of 10 assigned to the control group, received at least one erythrocyte transfusion during treatment. For all infants the amount of blood sampled for laboratory tests was strongly predictive of the volume of packed erythrocytes transfused (r=0.890; p=0.0001). Of nine infants who had <20 ml packed erythrocytes removed for laboratory tests, none of four given r-HuEPO received a transfusion, whereas three of five infants assigned to the placebo group received one. No toxic effects were attributable to r-HuEPO, and no significant changes in leukocyte or platelet counts occurred during treatment. Reticulocyte counts were correlated with simultaneous platelet counts and were inversely related to absolute neutrophil counts in both study groups. We conclude that r-HuEPO administration is safe and feasible at the dose studied. Additional controlled trials utilizing higher doses of r-HuEPO and larger numbers of patients are justified. Experimental and clinical data implicate inadequate erythropoletin production as an important reason that infants acquire this anemia and suggest that recombinant human erythropoletin (r-HuEPO) might be used to treat or prevent it. We therefore randomly assigned 20 small premature infants (birth weight ≤1250 gm) who were highly likely to require erythrocyte transfusions for anemia of prematurity to receive 6 weeks of treatment with either intravenously administered r-HuEPO (at a dose of 100 units/kg twice each week) or a placebo. Hematologic measurements, transfusion requirements, and growth were followed during therapy and for 6 months thereafter. Treated (EPO) and control babies did not differ with respect to weight, hematocrit, overall mean absolute reticulocyte count, calculated erythrocyte mass, or rate of growth. However, reticulocyte counts increased earlier in patients given r-HuEPO. Six of ten babies in the EPO group, and 8 of 10 assigned to the control group, received at least one erythrocyte transfusion during treatment. For all infants the amount of blood sampled for laboratory tests was strongly predictive of the volume of packed erythrocytes transfused (r=0.890; p=0.0001). Of nine infants who had <20 ml packed erythrocytes removed for laboratory tests, none of four given r-HuEPO received a transfusion, whereas three of five infants assigned to the placebo group received one. No toxic effects were attributable to r-HuEPO, and no significant changes in leukocyte or platelet counts occurred during treatment. Reticulocyte counts were correlated with simultaneous platelet counts and were inversely related to absolute neutrophil counts in both study groups. We conclude that r-HuEPO administration is safe and feasible at the dose studied. Additional controlled trials utilizing higher doses of r-HuEPO and larger numbers of patients are justified." @default.
• W1997559766 created "2016-06-24" @default.
• W1997559766 creator A5023734568 @default.
• W1997559766 creator A5024583939 @default.
• W1997559766 creator A5037346707 @default.
• W1997559766 creator A5054935604 @default.
• W1997559766 creator A5060439895 @default.
• W1997559766 creator A5068097628 @default.
• W1997559766 creator A5081979274 @default.
• W1997559766 creator A5082267944 @default.
• W1997559766 creator A5089107674 @default.
• W1997559766 date "1991-06-01" @default.
• W1997559766 modified "2023-10-18" @default.
• W1997559766 title "Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study" @default.
• W1997559766 cites W1966298541 @default.
• W1997559766 cites W1984943521 @default.
• W1997559766 cites W2019233486 @default.
• W1997559766 cites W2029738096 @default.
• W1997559766 cites W2055388734 @default.
• W1997559766 cites W2059963157 @default.
• W1997559766 cites W2063867610 @default.
• W1997559766 cites W2067581356 @default.
• W1997559766 cites W2069993100 @default.
• W1997559766 cites W2074496171 @default.
• W1997559766 cites W2074800607 @default.
• W1997559766 cites W2148174441 @default.
• W1997559766 cites W2152493043 @default.
• W1997559766 cites W2312612422 @default.
• W1997559766 cites W2315613377 @default.
• W1997559766 cites W2418112081 @default.
• W1997559766 cites W4249832396 @default.
• W1997559766 doi "https://doi.org/10.1016/s0022-3476(05)82217-6" @default.
• W1997559766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2040933" @default.
• W1997559766 hasPublicationYear "1991" @default.
• W1997559766 type Work @default.
• W1997559766 sameAs 1997559766 @default.
• W1997559766 citedByCount "128" @default.
• W1997559766 countsByYear W19975597662012 @default.
• W1997559766 countsByYear W19975597662013 @default.
• W1997559766 countsByYear W19975597662014 @default.
• W1997559766 countsByYear W19975597662016 @default.
• W1997559766 countsByYear W19975597662017 @default.
• W1997559766 countsByYear W19975597662018 @default.
• W1997559766 countsByYear W19975597662019 @default.
• W1997559766 countsByYear W19975597662020 @default.
• W1997559766 countsByYear W19975597662022 @default.
• W1997559766 crossrefType "journal-article" @default.
• W1997559766 hasAuthorship W1997559766A5023734568 @default.
• W1997559766 hasAuthorship W1997559766A5024583939 @default.
• W1997559766 hasAuthorship W1997559766A5037346707 @default.
• W1997559766 hasAuthorship W1997559766A5054935604 @default.
• W1997559766 hasAuthorship W1997559766A5060439895 @default.
• W1997559766 hasAuthorship W1997559766A5068097628 @default.
• W1997559766 hasAuthorship W1997559766A5081979274 @default.
• W1997559766 hasAuthorship W1997559766A5082267944 @default.
• W1997559766 hasAuthorship W1997559766A5089107674 @default.
• W1997559766 hasConcept C104317684 @default.
• W1997559766 hasConcept C105580179 @default.
• W1997559766 hasConcept C126322002 @default.
• W1997559766 hasConcept C141071460 @default.
• W1997559766 hasConcept C142724271 @default.
• W1997559766 hasConcept C185592680 @default.
• W1997559766 hasConcept C187212893 @default.
• W1997559766 hasConcept C204787440 @default.
• W1997559766 hasConcept C27081682 @default.
• W1997559766 hasConcept C2778248108 @default.
• W1997559766 hasConcept C2778403015 @default.
• W1997559766 hasConcept C2778534260 @default.
• W1997559766 hasConcept C2778917026 @default.
• W1997559766 hasConcept C2779234561 @default.
• W1997559766 hasConcept C2780959883 @default.
• W1997559766 hasConcept C54355233 @default.
• W1997559766 hasConcept C55493867 @default.
• W1997559766 hasConcept C66322754 @default.
• W1997559766 hasConcept C71924100 @default.
• W1997559766 hasConcept C86803240 @default.
• W1997559766 hasConcept C89560881 @default.
• W1997559766 hasConcept C90924648 @default.
• W1997559766 hasConceptScore W1997559766C104317684 @default.
• W1997559766 hasConceptScore W1997559766C105580179 @default.
• W1997559766 hasConceptScore W1997559766C126322002 @default.
• W1997559766 hasConceptScore W1997559766C141071460 @default.
• W1997559766 hasConceptScore W1997559766C142724271 @default.
• W1997559766 hasConceptScore W1997559766C185592680 @default.
• W1997559766 hasConceptScore W1997559766C187212893 @default.
• W1997559766 hasConceptScore W1997559766C204787440 @default.
• W1997559766 hasConceptScore W1997559766C27081682 @default.
• W1997559766 hasConceptScore W1997559766C2778248108 @default.
• W1997559766 hasConceptScore W1997559766C2778403015 @default.
• W1997559766 hasConceptScore W1997559766C2778534260 @default.
• W1997559766 hasConceptScore W1997559766C2778917026 @default.
• W1997559766 hasConceptScore W1997559766C2779234561 @default.
• W1997559766 hasConceptScore W1997559766C2780959883 @default.
• W1997559766 hasConceptScore W1997559766C54355233 @default.
• W1997559766 hasConceptScore W1997559766C55493867 @default.
• W1997559766 hasConceptScore W1997559766C66322754 @default.
• W1997559766 hasConceptScore W1997559766C71924100 @default.
• W1997559766 hasConceptScore W1997559766C86803240 @default.

• next